• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma.

作者信息

Vaccaro Mario, Bertino Lucrezia, Santarpia Mariacarmela, Altavilla Giuseppe, Cannavò Serafinella P

机构信息

Department of Clinical and Experimental Medicine-Dermatology, University of Messina, Messina, Italy.

Department of Human Pathology "G. Barresi", Medical Oncology Unit, University of Messina, Messina, Italy.

出版信息

Dermatol Ther. 2020 Nov;33(6):e14417. doi: 10.1111/dth.14417. Epub 2020 Oct 23.

DOI:10.1111/dth.14417
PMID:33068047
Abstract
摘要

相似文献

1
Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma.西米普利单抗治疗局部晚期皮肤鳞状细胞癌期间的放射回忆反应
Dermatol Ther. 2020 Nov;33(6):e14417. doi: 10.1111/dth.14417. Epub 2020 Oct 23.
2
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.西妥昔单抗治疗局部晚期皮肤鳞状细胞癌：一项开放标签、2 期、单臂试验的结果。
Lancet Oncol. 2020 Feb;21(2):294-305. doi: 10.1016/S1470-2045(19)30728-4. Epub 2020 Jan 14.
3
Novel treatment of locally advanced cutaneous squamous cell carcinoma with cemiplimab: a case report.西米普利单抗治疗局部晚期皮肤鳞状细胞癌的新疗法：病例报告
Int J Dermatol. 2021 Feb;60(2):233-235. doi: 10.1111/ijd.15176. Epub 2020 Sep 21.
4
Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation.肾移植后晚期皮肤鳞状细胞癌患者成功使用西米普利单抗治疗
JCO Oncol Pract. 2020 Mar;16(3):137-138. doi: 10.1200/JOP.19.00567. Epub 2019 Nov 26.
5
RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.瑞弗西单抗：首个获批用于治疗转移性或不可切除性皮肤鳞状细胞癌的药物。
Actas Dermosifiliogr (Engl Ed). 2020 Mar;111(2):161-163. doi: 10.1016/j.ad.2018.10.025. Epub 2019 Dec 24.
6
CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.西普单抗-rwlc 生存和流行病学研究在晚期皮肤鳞状细胞癌。
Future Oncol. 2020 Feb;16(4):11-19. doi: 10.2217/fon-2019-0762. Epub 2020 Jan 17.
7
Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.西妥昔单抗：在晚期皮肤鳞状细胞癌中的应用评价。
Drugs. 2020 Jun;80(8):813-819. doi: 10.1007/s40265-020-01302-2.
8
Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.联合治疗方案及免疫机制以增强西米普利单抗治疗皮肤鳞状细胞癌的疗效
Expert Rev Anticancer Ther. 2022 Feb;22(2):237-238. doi: 10.1080/14737140.2022.2020652. Epub 2021 Dec 30.
9
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.评估西妥昔单抗在治疗晚期皮肤鳞状细胞癌成人患者中的价值：成本效益分析。
Value Health. 2021 Mar;24(3):377-387. doi: 10.1016/j.jval.2020.09.014. Epub 2021 Jan 22.
10
Cemiplimab: First Global Approval.西尼莫单抗：全球首次获批。
Drugs. 2018 Nov;78(17):1841-1846. doi: 10.1007/s40265-018-1012-5.

引用本文的文献

1
Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy.帕博利珠单抗诱发放疗后5年出现的回忆性皮炎。
Reports (MDPI). 2024 Nov 4;7(4):91. doi: 10.3390/reports7040091.
2
Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review.免疫检查点抑制剂治疗患者的放射性回忆性皮炎：一例报告及文献综述
Cureus. 2021 Jun 9;13(6):e15548. doi: 10.7759/cureus.15548. eCollection 2021 Jun.